Abstract
(L)-2,4-dihydroxybutyrate (DHB) is a versatile compound that can serve as a precursor for the synthesis of the methionine analog 2-hydroxy-4-(methylthio)butyrate and new advanced polymers. We previously implemented in Escherichia coli an artificial biosynthetic pathway for the aerobic production of DHB from glucose, which relies on the deamination of (L)-homoserine followed by the reduction of 2-oxo-4-hydroxybutyrate (OHB) and yields DHB by an enzyme-bearing NADH-dependent OHB reductase activity. Under aerobic conditions, using NADPH as a cofactor is more favorable for reduction processes. We report the construction of an NADPH-dependent OHB reductase and increased intracellular NADPH supply by metabolic engineering to improve DHB production. Key cofactor discriminating positions were identified in the previously engineered NADH-dependent OHB reductase (E. coli malate dehydrogenase I12V:R81A:M85Q:D86S:G179D) and tested by mutational scanning. The two point mutations D34G:I35R were found to increase the specificity for NADPH by more than three orders of magnitude. Using the new OHB reductase enzyme, replacing the homoserine transaminase with the improved variant Ec.AlaC A142P:Y275D and increasing the NADPH supply by overexpressing the pntAB gene encoding the membrane-bound transhydrogenase yielded a strain that produced DHB from glucose at a yield of 0.25 molDHB molGlucose−1 in shake-flask experiments, which corresponds to a 50% increase compared to previous producer strains. Upon 24 h of batch cultivation of the most advanced DHB producer strain constructed in this work, a volumetric productivity of 0.83 mmolDHB L−1 h−1 was reached.
1 Introduction
(L)-2,4-dihydroxybutyrate (DHB) is a versatile compound of growing industrial relevance, as it can serve as a precursor for the chemical production of the methionine analog 2-hydroxy-4-(methylthio)butyrate (HMTB) used in animal nutrition () or as a building block for new advanced biopolymers (). Furthermore, DHB can serve as a precursor for the synthesis of 1,3-propanediol () or 1,2,4-butanetriol (). Although the occurrence of DHB at trace levels in patients with succinic semialdehyde dehydrogenase deficiency has been described previously (), there is no annotated natural metabolic pathway for its biosynthesis.
Aided by synthetic biology and enzyme engineering, we and others have previously reported three artificial biosynthetic pathways for the aerobic, microbial production of DHB starting from the widely abundant and inexpensive sugar glucose (; ; ). It is of note, however, that all the new routes are fully compatible with the use of other sugars (e.g., xylose, mannose, sucrose) or alcohols (e.g., methanol, ethylene glycol) as starting carbon sources, as all DHB pathways start from naturally occurring metabolites (homoserine, malate, or glyoxylate/acetyl-CoA). The different metabolic routes were tested in Escherichia coli. The highest reported titers (7.9 ± 0.01 mM) and yields (0.10 ± 0.01 molDHB molGlucose−1) in shake-flask cultivations with glucose as carbon source have been achieved with the DHB pathway proceeding through the characteristic natural intermediate (L)-homoserine (). This route enables DHB synthesis via sequential deamination of (L)-homoserine by homoserine transaminase activity and reduction of 2-oxo-4-hydroxybutyrate (OHB) by an OHB reductase activity (Figure 1). In a previous study, we reported the construction of the highly active NADH-dependent OHB reductase Ec.Mdh5Q (). The mutant variant descends from the parent NAD+-dependent (L)-malate dehydrogenase from E. coli (Ec.Mdh) and incorporates five mutations (I12V:R81A:M85Q:D86S:G179D) to yield the desired synthetic activity. However, the typical intracellular ratios of [NADH]/[NAD+] and [NADPH]/[NADP+] in E. coli cells cultivated under aerobic conditions are 0.03 and 60, respectively (), which suggests that the utilization of NADPH as a cofactor in aerobic reduction processes may be more favorable. Therefore, employing an enzyme bearing NADPH-dependent OHB reductase activity could provide a strong advantage in terms of pathway performance.
FIGURE 1
In the absence of annotated naturally occurring enzymes with NADPH-dependent OHB reductase activity, we chose NADH-dependent Ec.Mdh5Q as the template enzyme to engineer the required activity. Previous studies have focused on engineering the nicotinamide cofactor specificity of oxidoreductases following rational approaches [as reviewed by
2 Materials and methods
2.1 Reagents and chemicals
Unless stated otherwise, chemicals and solvents were purchased from Sigma-Aldrich (Darmstadt, Germany). Restriction enzymes and kits for plasmid DNA isolation, gel DNA extraction, and PCR clean-up were purchased from NEB (Frankfurt am Main, Germany) and used according to the manufacturer’s instructions. Primers were purchased from Sigma-Aldrich. Sanger sequencing was carried out by Genewiz (Leipzig, Germany).
2.2 Strains and plasmids
All strains and plasmids used in this study are listed in Tables 1, 2.
TABLE 1
| Plasmid | Relevant characteristic | Reference/Origin |
|---|---|---|
| pKD4 | R6K γ ori, FRT-flanked KanR, and AmpR | |
| pKD46 | pSC101 ori, araC-ParaB, λ-Red recombinase system (γ, β, exo, λ tL3 terminator), and AmpR | |
| pCP20 | pSC101 ori, AmpR, CmR, and Flp | |
| In vitro studies | ||
| pET28a(+) | f1 origin, KanR, and T7 promoter | Novagen™ |
| pET28-Ec-Mdh5Q | pET28a(+) derivative N-terminal His-tagged Ec.mdhR81A:M85Q:I12V:G179D:D86S | |
| pET28-Ec-Mdh5Q-D34G | pET28a(+) derivative with N-terminal His-tagged Ec.mdhR81A:M85Q:I12V:G179D:D86S:D34G | This study |
| pET28-Ec-Mdh5Q-D34G:I35K | pET28a(+) derivative with N-terminal His-tagged Ec.mdhR81A:M85Q:I12V:G179D:D86S:D34G:I35K | This study |
| pET28-Ec-Mdh5Q-D34G:I35R | pET28a(+) derivative with N-terminal His-tagged Ec.mdhR81A:M85Q:I12V:G179D:D86S:D34G:I35R | This study |
| pET28-Ec-Mdh5Q-D34G:I35S | pET28a(+) derivative with N-terminal His-tagged Ec.mdhR81A:M85Q:I12V:G179D:D86S:D34G:I35S | This study |
| pET28-Ec-Mdh5Q-D34G:I35T | pET28a(+) derivative with N-terminal His-tagged Ec.mdhR81A:M85Q:I12V:G179D:D86S:D34G:I35T | This study |
| In vivo DHB production | ||
| pZA23 | p15A origin, KanR, and PA1lacO-1 promoter | Expressys |
| pZA23-HS1-5Q | pZA23 derivative carrying Ec.thrAS345F, Ec.aspC, Ec.mdh5Q, and Ec.ppcK620S | |
| pZA23-HS1-7Q | pZA23 derivative harboring Ec.thrAS345F, Ec.aspC, Ec.mdh7Q, and Ec.ppcK620S | This study |
| pZA23-HS2-5Q | pZA23 derivative harboring Ec.thrAS345F, Ec.alaCA142P:Y275D, Ec.Mdh5Q, and Ec.ppcK620S | |
| pZA23-HS2-7Q | pZA23 derivative harboring Ec.thrAS345F, Ec.alaCA142P:Y275D, Ec.mdh7Q, and Ec.ppcK620S | This study |
Plasmids used in this study.
TABLE 2
| Strain | Genotype | Reference/Origin |
|---|---|---|
| NEB® 5-alpha | E. coli fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80Δ (lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 | NEB™ |
| BL21 (DE3) | E. coli fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS | NEB™ |
| MG1655 | F−λ-ilvG- rfb-50 rph-1 | ATCC |
| bWL1221 | E. coli MG1655 lldDproD-kan | INSA Toulouse |
| EcHS0 | E. coli MG1655 ΔthrB ΔmetA ΔldhA | This study |
| EcHS1 | EcHS0 with pZA23-HS1-5Q (Ec.aspC, Ec.mdh5Q) | This study |
| EcHS2 | EcHS0 with pZA23-HS1-7Q (Ec.aspC, Ec.mdh7Q) | This study |
| EcHS3 | EcHS0 with pZA23-HS2-5Q (Ec.alaCA142P:Y275D, Ec.mdh5Q) | This study |
| EcHS4 | EcHS0 with pZA23-HS2-7Q (Ec.alaCA142P:Y275D, Ec.mdh7Q) | This study |
| EcHS5 | EcHS3 with ΔpfkA | This study |
| EcHS6 | EcHS3 with ΔsthA | This study |
| EcHS7 | EcHS3 with pntABproD | This study |
| EcHS8 | EcHS7 with ΔsthA | This study |
| EcHS9 | EcHS4 with ΔpfkA | This study |
| EcHS10 | EcHS4 with ΔsthA | This study |
| EcHS11 | EcHS4 with pntABproD | This study |
| EcHS12 | EcHS11 with ΔsthA | This study |
Escherichia coli strains used in this study.
2.3 Media
For cloning procedures, protein production, and cell recovery from glycerol stocks (30% v/v) kept at −80°C, cells were cultivated in lysogeny broth (LB) medium (10 g L−1 tryptone, 5 g L−1 yeast extract and 10 g L−1 NaCl). LB agar plates were prepared by adding 20 g L−1 agar-agar to liquid LB.
For DHB production studies, cells were cultivated in M9 mineral medium (
2.4 Site-directed mutagenesis, gene expression, and protein purification for in vitro enzyme studies
Site-directed mutagenesis was performed via inverse PCR (
N-terminally 6x-His-tagged enzymes were produced in E. coli BL21 (DE3) cells harboring respective pET28a expression vectors. A volume of 50 mL of lysogeny broth (LB) medium supplemented with kanamycin in a 250 mL unbaffled shake flask was inoculated at an initial optical density at 600 nm (OD600) of 0.2 from an overnight LB culture. The culture was incubated at 37°C and 220 rpm. Heterologous protein expression was induced when OD600 = 0.6 by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) to the medium. When an OD600 of 2 was reached, cells were harvested by centrifugation (10 min, 4,000 ×g, 4°C), and the cell pellets were stored at −20°C until further analysis. To purify the His-tagged protein, frozen cell pellets were thawed on ice, resuspended in 50 mM HEPES buffer containing 300 mM NaCl (pH = 7.5), and then disrupted using a sonicator (UDS 751, TOPAS, Germany, 4 × 30 s, 30% amplitude). Cell debris was removed from the soluble protein fraction by centrifugation (17,500 ×g, 15 min, 4°C). Upon washing of the Talon™ Cobalt affinity resin (Clontech, United States) according to the supplier’s instructions, the crude extract was added to the resin and incubated in a tube rotator (VWR) at room temperature for 20 min. After binding, a washing step with 50 mM HEPES buffer containing 300 mM NaCl (pH = 7.5) and a subsequent washing step with the same buffer but additionally containing 15 mM imidazole (pH = 7.5) were carried out. Afterward, the protein bound to the resin was eluted with 200 mM imidazole in 50 mM HEPES buffer containing 300 mM NaCl (pH = 7.5) in a final volume of 500 µL. The concentration of purified protein was determined using the Bradford assay (Rotiquant®, Carl Roth), usually yielding a protein concentration of 3–4 mg mL−1 after purification.
2.5 OHB synthesis
OHB was prepared enzymatically starting from (L)-homoserine in a reaction catalyzed by the (L)-amino acid oxidase from Crotalus adamanteus (Sigma-Aldrich, A9253) as described by
2.6 OHB reductase assay
Enzymatic assays with purified enzyme were conducted at 37°C in 96-well flat-bottomed microtiter plates with a final reaction volume of 250 µL per well. The reaction kinetics were monitored in a microplate reader (NanoQuant Plate™, Infinite M200 PRO, TECAN) by following the characteristic absorption of NAD(P)H at 340 nm. The reaction mixture contained 0.25 mM NAD(P)H, 60 mM Hepes (pH 7.0, adjusted with 5 M KOH), 5 mM MgCl2, 50 mM KCl, and appropriate amounts of the purified enzyme. Reactions were started by adding 2 mM OHB to assess the cofactor preference of the constructed enzyme variants. To determine the kinetic constants on the substrate of Ec.Mdh5Q and top-performing NADPH-dependent OHB reductase, specific activities were determined at variable OHB concentrations (0.005–10 mM) and 0.25 mM of the preferred co-substrate. In order to estimate the kinetic constants on the cofactors, specific activities were determined at fixed amounts of substrate (OHB, 2 mM) and variable amounts of NAD(P)H (0.03–1 mM). Experimental data were fitted to the Michaelis–Menten model or to the substrate inhibition model using non-linear regression (Curve fitting tool, MATLAB R2021a). One unit (U) is defined as the amount of enzyme that catalyzes the conversion of 1 µmol of NAD(P)H per minute at pH 7.0 and 37°C. Km,app [mM] is defined as the apparent Michaelis–Menten constant, Ki [mM] is the substrate inhibition constant, vmax,app [U mg−1] is the apparent maximum reaction speed, and kcat,app is the apparent catalytic constant [s−1]. The catalytic efficiency is described by kcat/Km [mM s−1] (
2.7 Plasmid construction for in vivo DHB biosynthesis
All plasmids constructed and used for in vivo DHB synthesis are listed in Table 1. The vectors are based on the pZA23 backbone of the pZ expression system (Expressys). Plasmids pZA23-HS1-5Q (Ec.aspC, Ec.mdh5Q) and pZA23-HS2-5Q (Ec.alaCA142P:Y275D, Ec.mdh5Q) were a kind gift of Prof. J. M. François from Toulouse Biotechnology Institute, INSA Toulouse, France, and served as the basis for gene replacements. To replace OHB reductase-encoding gene Ec.mdh5Q, the gene Ec.mdh7Q was first amplified by PCR from the corresponding pET28 vector using the primers TW2949 and TW2427 listed in Supplementary Table S1, thereby introducing 5′ overhangs containing NotI and XbaI restriction sites. Backbone vectors pZA23-HS1-5Q and pZA23-HS2-5Q and insert were digested with the restriction enzymes NotI and XbaI (NEB). The digested backbone was further treated with Antarctic phosphatase (NEB). After DNA purification by gel extraction (Gel Extraction Kit, NEB), the backbone and insert were ligated using T4 DNA ligase (NEB) according to the provider’s protocol. After verification via sequencing, plasmids were transformed into appropriate host strains.
2.8 Strain construction
All E. coli strains constructed and used are listed in Table 2. Chromosomal gene deletions in E. coli MG1655 were introduced by P1vir phage transduction (
For chromosomal overexpression of Ec.pntAB, the native chromosomal 5′-untranslated region of the gene was replaced by the insulated constitutive promoter proD (
2.9 Shake-flask cultivation for DHB production
All cell cultivations were performed at 37°C, 220 rpm in an orbital shaker (Ecotron, Infors). First, pre-cultures were inoculated with a single colony picked from an LB agar plate and cultivated in 3 mL LB media (15 mL Falcon tube lying flat), and 50 μg mL−1 kanamycin was added to the strains harboring pZA23 plasmids. After 8 h, a volume of 0.5 mL of the first pre-culture was transferred to 10 mL of M9 mineral medium, supplemented with (L)-methionine (0.2 g L−1), (L)-threonine (0.2 g L−1), and kanamycin. After 16 h of cultivation, cells were harvested by centrifugation in a table-top centrifuge (5 min, 6,000 ×g, room temperature). The main cultures were carried out in 25 mL M9 media supplemented with (L)-methionine (0.2 g L−1), (L)-threonine (0.2 g L−1), and kanamycin in 250 mL baffled shake flasks. The main cultures were inoculated with the harvested cells at a starting OD600 of 0.2. When an OD600 of ∼0.6 was reached, 1 mM IPTG was added to induce the expression of pathway genes. Samples were regularly withdrawn and centrifuged (2 min, 16,000 ×g, room temperature), and the supernatant was kept at −20°C until further analysis.
2.10 Analytical methods
Extracellular metabolites (glucose, DHB, acetate, and lactate) in supernatant samples from cultivations were analyzed using HPLC. The samples (1 mL) were filter sterilized with 0.2 µm filters, transferred into 2 mL HPLC sample vials, and subsequently analyzed with the Dionex UltiMate 3000 UHPLC system (Thermo Scientific). The device was equipped with an RI and UV/Vis detector. For separation, a Rezex™ ROA-Organic Acid H+ (8%) column (Phenomenex) with a size of 300 mm × 7.8 mm was used, protected by a SecurityGuard™ Carbo H+ pre-column (4 mm × 3 mm, Phenomenex). A sample volume of 20 µL was injected, and analytes were eluted using 0.5 mM H2SO4 as mobile phase, with a flow rate of 0.5 mL min−1. The column oven temperature was set to 80°C, and the temperature of the autosampler was set to 6°C.
Depending on the concentration range, the presence of DHB was verified by LC/MS analyses using our previously described method (
2.11 Computational methods
Multiple sequence alignment of NAD(P)H-dependent malate dehydrogenases and lactate dehydrogenases was performed using MAFFT (v 7.525) provided by EMBL-EBI (
3 Results
3.1 Strategy for the design of NADPH-dependent OHB reductase activity
We have previously engineered a highly active OHB reductase using the NAD+-dependent (L)-malate dehydrogenase from E. coli (Ec.Mdh; UniProtKB code P61889) as a template enzyme. The best-performing variant, Ec.Mdh5Q, contains five point mutations (I12V:R81A:M85Q:D86S:G179D) and displays a 108-fold higher catalytic efficiency with NADH than with NADPH (Figure 2A). Because the typical intracellular ratios of [NAD(P)H]/[NAD(P)] in E. coli (
FIGURE 2

Specific activity of Ec.Mdh5Q on OHB with NAD(P)H and 3D-protein structures with NAD+ or NADP+. (A) Catalytic efficiency (kcat,app/KM,app) of Ec.Mdh5Q with NAD(P)H. Enzymatic activity was measured with purified enzyme at 37°C and pH 7.0 in 96-well flat-bottomed microtiter plates with 2 mM OHB and 0.25 mM NAD(P)H. The reactions were followed by monitoring the NAD(P)H absorption at 340 nm. Error bars indicate the standard deviation of the mean (n = 2). (B) X-ray structure of Ec.Mdh with bound NAD+ (Pdb code: 1emd). Side chains of amino acids in the selectivity control loop are shown (positions 34–38). (C) X-ray structure of Ec.Mdh with superimposed NADP+. The figure was generated by the structural alignment of Ec.Mdh with bound NAD (Pdb code: 1emd) and the malate dehydrogenase from Flaveria bidentis (Fb.Mdh) with bound NADP (Pdb code: 1civ). The structures of Fb-Mdh and NAD were omitted from the representation. (D) Model structure of Ec.Mdh D34G:I35S with superimposed NADP+. The figure was generated by structural alignment of the mutant enzyme model [generated with AlphaFold Colab (
NAD+-dependent (L)-malate dehydrogenases (cytosolic; Mdh type 1 family) belong to the large superfamily of (L)-Mdh/(L)-Ldh enzymes, which further includes NADP+-dependent enzymes of identical function (chloroplastic; Mdh type 2 family) and NAD+-dependent (L)-lactate dehydrogenases (Ldh). Multiple sequence alignments between several members of the superfamily of Mdh and Ldh enzymes revealed a strong conservation of the primary protein structure (Supplementary Figure S1). Previous studies elucidated the crucial role of a loop region in a conserved cofactor binding motif of the Rossman fold for cofactor discrimination (
3.2 In vitro analysis of OHB reductase mutants
Point mutations to switch cofactor preference were stepwise introduced into the Ec.mdh5Q gene by site-directed mutagenesis. The constructed N-terminally 6x-His-tagged variants were expressed from pET28a vectors transformed in E. coli BL21(DE3) cells. After purification, the specific activity of the purified variants was first quantified in the presence of OHB (2 mM) and either NADH or NADPH (0.25 mM) as cofactor. As shown in Figure 3, the template enzyme Ec.Mdh5Q was highly active on OHB with NADH as a co-substrate (68 ± 4 U mg−1) but displayed low activity in the presence of NADPH (4 ± 0.2 U mg−1). For all of the engineered mutants, the cofactor preference (here defined as v(NADPH)/v(NADH)) was found to be altered. Replacement of the Asp34 residue by glycine resulted in comparable OHB reductase activity in the presence of both cofactors (v(NADH) = 23 ± 2 U mg−1, v(NADPH) = 35 ± 3 U mg−1), possibly indicating dual cofactor preference. The additional substitution of isoleucine at position 35 by serine, threonine, lysine, or arginine resulted in at least 2.5-fold higher activities in the presence of NADPH than NADH. With 64 ± 4.5 U mg−1, the specific OHB reductase activity of Ec.Mdh5Q D34G:I35R (hereafter abbreviated as Ec.Mdh7Q) with NADPH as a cofactor was nearly six-fold higher than with NADH (12 ± 0.02 U mg−1). The mutant variant showed a similar specific activity on OHB when compared to that of Ec.Mdh5Q. Thus, Ec.Mdh7Q was identified as the most promising NADPH-dependent OHB reductase enzyme, and its kinetic parameters on both cofactors and OHB were determined and compared to those of Ec.Mdh5Q.
FIGURE 3

Specific NAD(P)H-dependent OHB reductase activity of engineered variants derived from Ec.Mdh5Q. The enzymes were produced from E. coli BL21 (DE3) harboring the respective pET28a expression vectors cultivated in 50 mL LB. Heterologous expression was induced at OD600 of 0.6 with 1 mM IPTG. Protein expression was carried out until OD600 = 2 was reached. Enzymatic assays were performed with purified enzyme at 37°C and pH 7.0 in 96-well flat-bottomed microtiter plates with 2 mM OHB and 0.25 mM NAD(P)H. The reactions were followed by monitoring the NAD(P)H absorption at 340 nm. Error bars indicate the standard deviation of the mean (n = 2).
The kinetic parameters of both enzyme variants are summarized in Table 3. The engineered variant Ec.Mdh7Q exhibited more than three orders of magnitude higher specificity (defined as (kcat/Km(NADPH))/(kcat/Km(NADH)) for NADPH than Ec.Mdh5Q (16 and 0.01, respectively). No loss in OHB affinity or impairment of the overall catalytic efficiency ((kcat/Km)OHB × (kcat/Km)NAD(P)H) was observed. We observed uncompetitive substrate inhibition of Ec.Mdh7Q by OHB (Ki = 5.5 ± 0.5 mM). Substrate inhibition was found to be stronger than for Ec.Mdh5Q (Ki = 31.9 mM ± 5.6 mM) (
TABLE 3
| Enzyme | Ec.Mdh5Q | Ec.Mdh7Q |
|---|---|---|
| NADHa | ||
| Vmax,app (U mg−1) | 67.68 (±3.12) | 20.02 (±1.99) |
| kcat,app (s−1) | 36.48 (±1.68) | 10.79 (±1.07) |
| Km,app (mM) | 0.04 (±0.004) | 0.27 (±0.04) |
| kcat,app/Km,app (mM−1 s−1) | 1,027.40 (±67.46) | 40.35 (±1.71) |
| NADPHa | ||
| Vmax,app (U mg−1) | 5.56 (±0.64) | 118.80 (±18.5) |
| kcat,app (s−1) | 2.99 (±0.35) | 64.03 (±9.97) |
| Km,app (mM) | 0.32 (±0.04) | 0.10 (±0.03) |
| kcat,app/Km,app (mM−1 s−1) | 9.50 (±0.05) | 645.47 (±76.25) |
| OHBb | ||
| Vmax,app (U mg−1) | 138.50 (±10.45) | 154.80 (±6.30) |
| kcat,app (s−1) | 74.89 (±5.63) | 83.43 (±3.40) |
| Km,app (mM) | 1.84 (±0.50) | 1.08 (±0.19) |
| Ki (mM) | 31.9 (±5.6)c | 5.45 (±0.48) |
| kcat,app/Km,app (mM−1 s−1) | 44.91 (±15.18) | 80.29 (±17.27) |
| Specificity | ||
| (kcat,app/Km,app)NADPH/(kcat,app/Km,app)NADH | 0.01 | 16.00 |
| Overall catalytic efficiency | ||
| (kcat,app/Km,app)OHB × (kcat,app/Km,app)NAD(P)H | 46,136 | 51,823 |
Kinetic analysis of OHB reductases Ec.Mdh5Q and Ec.Mdh7Q.
Specific OHB reductase activities were determined at fixed concentrations of substrate (OHB, 2 mM) and variable concentrations of NAD(P)H (1–0.03 mM).
Specific OHB reductase activities were determined at fixed concentrations (0.25 mM) of the preferred co-substrate NAD(P)H and variable amounts of OHB (10–0.005 mM).
Apparent kinetic constants (Km,app, Vmax,app) were estimated by fitting the experimental data to the Michaelis–Menten model using non-linear regression unless enzymes displayed substrate inhibition kinetics (Curve fitting tool, MATLAB R2021a). To calculate the apparent catalytic constant kcat,app, the molecular weight of one subunit of Ec.Mdh (32.337 kDa) was considered. Specificity and efficiency were calculated based on mean kcat,app and Km,app values. Enzyme assays were performed in biological duplicates. Ec.Mdh5Q contains mutations I12V:R81A:M85Q:D86S:G179D.
Ec.Mdh7Q additionally contains mutations D34G:I35R.
3.3 DHB production using NADPH-dependent OHB reductase
Next, the in vivo performance of the NADPH-dependent OHB reductase Ec.Mdh7Q for DHB biosynthesis was investigated. To achieve DHB production from glucose, we selected E. coli MG1655 ΔthrB ΔmetA ΔldhA as a production host to ensure a sufficient supply of the homoserine precursor. The host was then equipped with a DHB pathway consisting of homoserine transaminase activity (catalyzed by Ec.AspC from E. coli), and NAD(P)H-dependent OHB reductase activity (either Ec.Mdh5Q or Ec.Mdh7Q) expressed from a medium-copy plasmid pZA23 under the control of the ITPG-inducible PA1lacO-1 promoter. Constructed plasmids additionally carried threonine-insensitive bifunctional aspartate kinase/homoserine dehydrogenase (Ec.ThrAS345F) and the aspartate/malate insensitive phosphoenolpyruvate carboxylase variant Ec.PpcK620S (
Producer strains were cultivated in 25 mL M9 mineral medium containing 20 g L−1 glucose. (L)-methionine and (L)-threonine were added to the medium (at a final concentration of 0.2 g L−1 each) to compensate for the host strain’s auxotrophies. Expression of pathway genes was induced by IPTG (1 mM) at the mid-exponential phase, and DHB production was quantified after 24 h of cell cultivation. Upon expression of Ec.Mdh5Q, we found the culture supernatant to contain 7.0 ± 0.5 mM DHB (EcHS1, Figure 4), reaching a product yield of 0.10 ± 0.004 molDHB molGlucose−1 and a volumetric productivity of 0.29 ± 0.02 mmolDHB L−1 h−1. Strain EcHS2 expressing Ec.Mdh7Q was able to produce 7.5 ± 0.6 mM DHB. Because only a modest increase in DHB production was observed with NADPH-dependent OHB reductase, we speculated at this stage that homoserine transaminase activity was limiting. Indeed, purified Ec.AspC enzyme has previously been shown to display only low in vitro activity on (L)-homoserine (0.082 U mg−1), and it could not be saturated at substrate concentrations of up to 50 mM (L)-homoserine (
FIGURE 4

DHB concentration and yield after 24 h cultivation of engineered production strains. All strains are derived from the parental strain E. coli MG1655 ΔthrB ΔmetA ΔldhA, which was transformed with medium-copy DHB production plasmids expressing homoserine transaminase (Ec.aspC or Ec.alaCA142P:Y275D) and OHB reductase (Ec.Mdh5Q or Ec.Mdh7Q). All plasmids further carry Ec.thrAS345F and Ec.ppcK620S. Cultivation was performed at 37°C and 220 rpm in 250 mL baffled flasks containing 25 mL M9 medium with 20 g L−1 glucose, supplemented with 0.2 g L−1 (L)-methionine and 0.2 g L−1 (L)-threonine. The expression of pathway genes was induced at an OD600 of 0.6 with 1 mM IPTG. DHB titers and yields after 24 h of cultivation are shown. The experiments were performed in biological duplicates. Error bars indicate the standard deviation of the mean.
3.4 Construction of NADPH over-producing strain for improved DHB production
To demonstrate the full potential of NADPH-dependent OHB reductase toward DHB production, we next engineered the host strain E. coli MG1655 ΔthrB ΔmetA ΔldhA toward increased NADPH supply. We selected multiple chromosomal targets previously shown to increase the intracellular availability of NADPH, including the deletion of the Ec.pfkA gene (encoding 6-phosphofructokinase I) to enhance flux through the pentose phosphate pathway (
After 24 h of cultivation in glucose-containing mineral medium, the producer strains with the chromosomal deletion of the Ec.pfkA gene and expressing the NADH-dependent Ec.mdh5Q (EcHS5) exhibited a severe drop of both DHB concentration and yield when compared to the reference strain EcHS3 (Figure 5). This may be related to the observed growth defect caused by Ec.pfkA deletion (data not shown). With EcHS6 deleted for Ec.sthA, the DHB yield was equal to 0.19 ± 0.03 molDHB molGlucose−1, which corresponds to a 19% increase when compared to reference strain EcHS3 with a yield of 0.16 mol ± 0.001 molDHB molGlucose−1. Upon chromosomal overexpression of Ec.pntAB (EcHS7), the product yield was further increased to 0.21 ± 0.007 molDHB molGlucose−1, which corresponds to a total increase of 30% compared to the reference strain (EcHS3). The additional deletion of Ec.sthA did not provide an advantage and indeed caused the DHB yield to drop to 0.18 ± 0.008 molDHB molGlucose−1.
FIGURE 5

DHB concentration and yield after 24 h cultivation of engineered production strains with increased NADPH availability. All strains were derived from the parental strain E. coli MG1655 ΔthrB ΔmetA ΔldhA, which was transformed with medium-copy DHB production plasmids expressing homoserine transaminase (Ec.alaCA142P:Y275D) and OHB reductase (Ec.mdh5Q or Ec.mdh7Q). All plasmids further carried Ec.thrAS345F and Ec.ppcK620S. Cultivation was performed at 37°C and 220 rpm in 250-mL baffled flasks containing 25 mL M9 medium with 20 g L−1 glucose, supplemented with 0.2 g L−1 (L)-methionine and 0.2 g L−1 (L)-threonine. Expression of pathway genes was induced at an OD600 of 0.6 with 1 mM IPTG. DHB titers and yields after 24 h of cultivation are shown. The experiments were performed in biological duplicates. Error bars indicate the standard deviation of the mean.
The production strains expressing Ec.mdh7Q displayed similar tendencies as the strains expressing Ec.mdh5Q. However, the positive effect on DHB production upon chromosomal overexpression of Ec.pntAB was enhanced, yielding 0.25 ± 0.01 molDHB molGlucose−1 after 24 h cultivation of EcHS11. Thus, increased NADPH availability via chromosomal overexpression of pntAB promoted DHB synthesis, particularly in the presence of the engineered NADPH-dependent enzyme variant.
To sum up, by co-expression of the improved homoserine transaminase (Ec.alaCA142P:Y275D) with the NADPH-dependent OHB reductase Ec.mdh7Q and by further modification of the production strain (Ec.pntABproD), it was possible to increase the DHB yield by 50% to 0.25 ± 0.01 molDHB molGlucose−1 and reach a volumetric productivity of 0.83 ± 0.03 mmolDHB L−1 h−1 within 24 h of batch cultivation of EcHS11.
3.5 Discussion
In previous work, we used a rational engineering approach to construct a highly active OHB reductase enzyme, catalyzing the last reaction step of the artificial homoserine-dependent DHB synthesis route (
Oxidoreductases with nicotinamide cofactor dependency exhibit a strong preference for either NAD(H) or NADP(H) (
Previous studies investigating the cofactor specificity of enzymes belonging to the (L)-malate/(L)-lactate dehydrogenase superfamily revealed that only a few amino acid residues are responsible for conferring the preference for either NAD(H) or NADP(H). In attempts to reverse the enzyme cofactor dependency, identifying crucial cofactor-discriminating key positions is usually followed by site-directed mutagenesis of the respective amino acid residues or a loop exchange approach (
When we first replaced the NADH-dependent OHB reductase with our engineered NADPH-dependent variant for in vivo DHB production via the homoserine-dependent pathway, a positive effect could not be observed. Thus, we speculated that our current transaminase, Ec.AspC, was limiting the pathway flux (Figure 4). By exchanging Ec.AspC with the alanine aminotransferase double mutant Ec.AlaCA142P:Y275D (
Several studies showed how increased NADPH availability resulted in higher yields and productivities of NADPH-dependent product formations. To show the full potential of our engineered NADPH-dependent OHB reductase, we engineered the host strain toward increased NADPH availability using common strategies, including chromosomal deletion of Ec.pfkA to increase the flux through the PPP, deletion of Ec.sthA, and chromosomal overexpression of Ec.pntAB (
In a larger, more general context, our study shows how streamlining NADPH cofactor preference of the biosynthetic pathway (by enzyme engineering) and NADPH cofactor supply (by metabolic engineering) can increase the efficiency of aerobic biosyntheses of reduced compounds.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.
Author contributions
NI: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing. LG: Investigation, Writing – review & editing. CA: Investigation, Writing – review & editing. TN: Investigation, Writing – review & editing. TW: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing. CF: Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by a grant from ERA-CoBioTech (ID: 20) awarded to TW. This project is co-funded by the European Union and co-financed from tax revenues on the basis of the budget adopted by the Saxon State Parliament (Project number 100549942). The LC/MS system was in part founded by the Deutsche Forschungsgemeinschaft (INST 269/792-1 FUGG).
Acknowledgments
The authors thank Prof. Jean-Marie François for the helpful discussions and for kindly providing the strain bWL1221.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2025.1504785/full#supplementary-material
References
1
BabaT.AraT.HasegawaM.TakaiY.OkumuraY.BabaM.et al (2006). Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol.2, 2006.0008. 10.1038/msb4100050
2
BennettB. D.KimballE. H.GaoM.OsterhoutR.Van DienS. J.RabinowitzJ. D. (2009). Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol.5 (8), 593–599. 10.1038/nchembio.186
3
BoonstraB.FrenchC. E.WainwrightI.BruceN. C. (1999). The UdhA gene of Escherichia coli encodes a soluble pyridine nucleotide transhydrogenase. J. Bacteriol.181 (3), 1030–1034. 10.1128/JB.181.3.1030-1034.1999
4
BouzonM.PerretA.LoreauO.DelmasV.PerchatN.JeanW.et al (2017). A synthetic alternative to canonical one-carbon metabolism. ACS Synth. Biol.6 (8), 1520–1533. 10.1021/acssynbio.7b00029
5
Brochier-ArmanetC.MadernD. (2021). Phylogenetics and biochemistry elucidate the evolutionary link between L-malate and L-lactate dehydrogenases and disclose an intermediate group of sequences with mix functional properties. Biochimie191, 140–153. 10.1016/j.biochi.2021.08.004
6
CabulongR. B.ValdehuesaK. N. G.BañaresA. B.RamosK. R. M.NisolaG. M.LeeW. K.et al (2019). Improved cell growth and biosynthesis of glycolic acid by overexpression of membrane-bound pyridine nucleotide transhydrogenase. J. Industrial Microbiol. Biotechnol.46 (2), 159–169. 10.1007/s10295-018-2117-2
7
CahnJ. K. B.WerlangC. A.BaumschlagerA.Brinkmann-ChenS.MayoS. L.ArnoldF. H. (2017). A general tool for engineering the NAD/NADP cofactor preference of oxidoreductases. ACS Synth. Biol.6 (2), 326–333. 10.1021/acssynbio.6b00188
8
ChániqueA. M.ParraL. P. (2018). Protein engineering for nicotinamide coenzyme specificity in oxidoreductases: attempts and challenges. Front. Microbiol.9, 194. 10.3389/fmicb.2018.00194
9
ChenY.HuangL.YuT.YaoY.ZhaoM.PangA.et al (2024). Balancing the AspC and AspA pathways of Escherichia coli by systematic metabolic engineering strategy for high-efficient L-homoserine production. ACS Synth. Biol.13, 2457–2469. 10.1021/acssynbio.4c00208
10
CherepanovP. P.WilfriedW. (1995). Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of flp-catalyzed excision of the Antibiotic-resistance determinant. Gene158 (1), 9–14. 10.1016/0378-1119(95)00193-A
11
ChinJ. W.CirinoP. C. (2011). Improved NADPH supply for xylitol production by engineered Escherichia coli with glycolytic mutations. Biotechnol. Prog.27 (2), 333–341. 10.1002/btpr.559
12
ChmielH. (2018). Bioprozesstechnik. 4th edn, Editors ChmielH.TakorsR.Weuster-BotzD. (Berlin, Heidelberg: Springer Berlin Heidelberg). 10.1007/978-3-662-54042-8
13
ClarkeD. M.LooT. W.GilliamS.BraggP. D. (1986). Nucleotide sequence of the PntA and PntB genes encoding the pyridine nucleotide transhydrogenase of Escherichia coli. Eur. J. Biochem.158 (3), 647–653. 10.1111/j.1432-1033.1986.tb09802.x
14
CrétinC.LuchettaP.JolyC.DecottigniesP.LepiniecL.GadalP.et al (1990). Primary structure of Sorghum malate dehydrogenase (NADP) deduced from CDNA sequence. Eur. J. Biochem.192 (2), 299–303. 10.1111/j.1432-1033.1990.tb19227.x
15
CuiY. Y.ChenL.YuanY. Z.HuangJ.LiuJ. Z. (2014). Production of shikimic acid from Escherichia coli through chemically inducible chromosomal evolution and cofactor metabolic engineering. Microb. Cell Factories13 (1), 1–11. 10.1186/1475-2859-13-21
16
DatsenkoK. A.WannerB. L. (2000). One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci.97 (12), 6640–6645. 10.1073/pnas.120163297
17
DavisJ. H.RubinA. J.SauerR. T. (2011). Design, construction and characterization of a set of insulated bacterial promoters. Nucleic Acids Res.39 (3), 1131–1141. 10.1093/nar/gkq810
18
FeeneyR.ClarkeA. R.HolbrookJ. J. (1990). A single amino acid substitution in lactate dehydrogenase improves the catalytic efficiency with an alternative coenzyme. Biochem. Biophysical Res. Commun.166 (2), 667–672. 10.1016/0006-291X(90)90861-G
19
FrançoisJ. M. (2023). Progress advances in the production of bio-sourced methionine and its hydroxyl analogues. Biotechnol. Adv.69, 108259. 10.1016/j.biotechadv.2023.108259
20
FrazaoC. J. R. (2019). Refactoring metabolic pathways for synthon production from renew-able carbon sources. Agricultural sciences. INSA de Toulouse
21
FrazãoC. J. R.TophamC. M.MalbertY.FrançoisJ. M.WaltherT. (2018). Rational engineering of a malate dehydrogenase for microbial production of 2,4-dihydroxybutyric acid via homoserine pathway. Biochem. J.475 (23), 3887–3901. 10.1042/BCJ20180765
22
FrazãoC. J. R.TrichezD.Serrano-BatailleH.DagkesamanskaiaA.TophamC. M.WaltherT.et al (2019). Construction of a synthetic pathway for the production of 1,3-propanediol from glucose. Sci. Rep.9 (1), 11576. 10.1038/s41598-019-48091-7
23
FrazãoC. J. R.WagnerN.KennyR.ThomasW. (2023). Construction of a synthetic metabolic pathway for biosynthesis of 2,4-dihydroxybutyric acid from ethylene glycol. Nat. Commun.14 (1), 1931. 10.1038/s41467-023-37558-x
24
HallM. D.BanaszakL. J. (1993). Crystal structure of a ternary complex of Escherichia coli malate dehydrogenase citrate and NAD at 1·9 Å resolution. J. Mol. Biol.232, 213–222. 10.1006/jmbi.1993.1377
25
HaoY.MaQ.LiuX.FanX.MenJ.WuH.et al (2020). High-yield production of L-valine in engineered Escherichia coli by a novel two-stage fermentation. Metab. Eng.62, 198–206. 10.1016/j.ymben.2020.09.007
26
HolmbergN.RydeU.BülowL. (1999). Redesign of the coenzyme specificity in L-lactate dehydrogenase from Bacillus stearothermophilus using site-directed mutagenesis and media engineering. Protein Eng.12 (10), 851–856. 10.1093/protein/12.10.851
27
JumperJ.EvansR.PritzelA.GreenT.FigurnovM.RonnebergerO.et al (2021). Highly accurate protein structure prediction with AlphaFold. Nature596 (7873), 583–589. 10.1038/s41586-021-03819-2
28
KabusA.GeorgiT.WendischV. F.BottM. (2007). Expression of the Escherichia coli PntAB genes encoding a membrane-bound transhydrogenase in corynebacterium glutamicum improves l-lysine formation. Appl. Microbiol. Biotechnol.75 (1), 47–53. 10.1007/s00253-006-0804-9
29
LemaireM.Miginiac-MaslowM.DecottigniesP. (1996). The catalytic site of chloroplastic NADP-dependent malate dehydrogenase contains a his/Asp pair. Eur. J. Biochem.236 (3), 947–952. 10.1111/j.1432-1033.1996.00947.x
30
LennoxE. S. (1955). Transduction of linked genetic characters of the host by bacteriophage P1. Virology1 (2), 190–206. 10.1016/0042-6822(55)90016-7
31
LiX.CaiZ.LiY.ZhangY. (2014). Design and construction of a non-natural malate to 1,2,4-butanetriol pathway creates possibility to produce 1,2,4-butanetriol from glucose. Sci. Rep.4 (1), 5541. 10.1038/srep05541
32
LiangQ.ZhangF.LiY.ZhangXuLiJ.YangP.et al (2015). Comparison of individual component deletions in a glucose-specific phosphotransferase system revealed their different applications. Sci. Rep.5 (1), 13200. 10.1038/srep13200
33
LiuY.ZhangJ.LiR.YuB. (2022). Efficient production of 2,4-dihydroxybutyrate from l -homoserine by the designed cofactor self-sufficient route. ACS Sustain. Chem. Eng.10, 14361–14369. 10.1021/acssuschemeng.2c05012
34
MadeiraF.MadhusoodananN.LeeJ.EusebiA.NiewielskaA.TiveyA. R. N.et al (2024). The EMBL-EBI job dispatcher sequence analysis tools framework in 2024. Nucleic Acids Res.52, W521–W525. 10.1093/nar/gkae241
35
MillardP.LetisseF.SokolS.PortaisJ. C. (2012). IsoCor: correcting MS data in isotope labeling experiments. Bioinformatics28 (9), 1294–1296. 10.1093/BIOINFORMATICS/BTS127
36
NgC.YuFarasatI.MaranasC. D.SalisH. M. (2015). Rational design of a synthetic entner-doudoroff pathway for improved and controllable NADPH regeneration. Metab. Eng.29, 86–96. 10.1016/j.ymben.2015.03.001
37
NishiyamaM.BirktoftJ. J.BeppuT. (1993). Alteration of coenzyme specificity of malate dehydrogenase from thermus flavus by site-directed mutagenesis. J. Biol. Chem.268 (7), 4656–4660. 10.1016/s0021-9258(18)53446-3
38
RathnasinghC.SubramanianM. R.LeeY.CatherineC.AshokS.ParkS. (2012). Production of 3-hydroxypropionic acid via malonyl-CoA pathway using recombinant Escherichia coli strains. J. Biotechnol.157 (4), 633–640. 10.1016/j.jbiotec.2011.06.008
39
RichterN.ZienertA.WernerH. (2011). A single-point mutation enables lactate dehydrogenase from Bacillus subtilis to utilize NAD+ and NADP+ as cofactor. Eng. Life Sci.11 (1), 26–36. 10.1002/elsc.201000151
40
RossmannM. G.MorasD.OlsenK. W. (1974). Chemical and biological evolution of a nucleotide-binding protein. Nature250 (5463), 194–199. 10.1038/250194a0
41
SauerU.CanonacoF.HeriS.PerrenoudA.FischerE. (2004). The soluble and membrane-bound transhydrogenases UdhA and PntAB have divergent functions in NADPH metabolism of Escherichia coli. J. Biol. Chem.279 (8), 6613–6619. 10.1074/jbc.M311657200
42
ShiA.ZhuX.LuJ.ZhangX.MaY. (2013). Activating transhydrogenase and NAD kinase in combination for improving isobutanol production. Metab. Eng.16 (1), 1–10. 10.1016/j.ymben.2012.11.008
43
ShinkaT.InoueY.OhseM.ItoA.OhfuM.HiroseS.et al (2002). Rapid and sensitive detection of urinary 4-hydroxybutyric acid and its related compounds by gas chromatography–mass spectrometry in a patient with succinic semialdehyde dehydrogenase deficiency. J. Chromatogr. B776 (1), 57–63. 10.1016/S1570-0232(02)00126-5
44
Takahashi-ÍñiguezT.Aburto-RodríguezN.Vilchis-GonzálezA. L.FloresM. E. (2016). Function, kinetic properties, crystallization, and regulation of microbial malate dehydrogenase. J. Zhejiang Univ. Sci. B17 (4), 247–261. 10.1631/jzus.B1500219
45
WaltherT.CalvayracF.MalbertY.AlkimC.DressaireC.CordierH.et al (2017a). Construction of a synthetic metabolic pathway for the production of 2,4-dihydroxybutyric acid from homoserine. Metab. Eng.45, 237–245. 10.1016/j.ymben.2017.12.005
46
WaltherT.DressaireC.CordierH.FrancoisJ.-M. (2015). Method of production of 2,4-dihydroxybutyric acid. U. S. 2015/0159182 A1.
47
WaltherT.TophamC. M.IragueR.AuriolC.BaylacA.CordierH.et al (2017b). Construction of a synthetic metabolic pathway for biosynthesis of the non-natural methionine precursor 2,4-dihydroxybutyric acid. Nat. Commun.8 (1), 15828. 10.1038/ncomms15828
48
WellnerD.LichtenbergL. A. (1971). [218a] Assay of amino acid oxidase. Methods Enzym.17, 593–596. 10.1016/0076-6879(71)17104-2
49
ZhangYuWeiM.ZhaoG.ZhangW.LiY.LinB.et al (2021). High-level production of L-homoserine using a non-induced, non-auxotrophic Escherichia coli chassis through metabolic engineering. Bioresour. Technol.327 (29), 124814. 10.1016/j.biortech.2021.124814
50
ZhengL.UlrichB.ReymondJ. L. (2004). An efficient one-step site-directed and site-saturation mutagenesis protocol. Nucleic Acids Res.32 (14), e115. 10.1093/nar/gnh110
Summary
Keywords
enzyme engineering, strain engineering, cofactor specificity, synthetic metabolic pathway, 2,4-dihydroxybutyric acid, homoserine, Escherichia coli
Citation
Ihle N, Grüßner L, Alkim C, Nguyen TAS, Walther T and Frazão CJR (2025) Cofactor engineering for improved production of 2,4-dihydroxybutyric acid via the synthetic homoserine pathway. Front. Bioeng. Biotechnol. 13:1504785. doi: 10.3389/fbioe.2025.1504785
Received
01 October 2024
Accepted
23 January 2025
Published
20 February 2025
Volume
13 - 2025
Edited by
Ruud Weusthuis, Wageningen University and Research, Netherlands
Reviewed by
Zhiming Rao, Jiangnan University, China
Roland Wohlgemuth, Lodz University of Technology, Poland
Updates

Check for updates
Copyright
© 2025 Ihle, Grüßner, Alkim, Nguyen, Walther and Frazão.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cláudio J. R. Frazão, claudio.frazao@tu-dresden.de
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.